Magnetic Moment

In terms of medical applications magnetic resonance imaging could serve, the modality is still underused, and that means a large, untapped growth opportunity for the entrenched large manufacturers that dominate the industry with an installed base of capital equipment. Small companies have a role to play as well, with adjunctive technologies that serve the large players, or in niches too small for the multi-billion dollar players to notice.

In 2003, the Nobel Prize awarded to Paul Lauterbur and Peter Mansfield for their contributions to magnetic resonance imaging (MRI) focused scientific recognition on this medical technology based on atomic physics, but real-world recognition has finally arrived as well. MRI is becoming a diagnostic standard for an increasing number of soft tissue applications–degenerative disc disease in the lower back, for example, and certain neurological indications, where it is used to diagnose multiple sclerosis and epilepsy. Technological improvements over the last ten years in image acquisition speed and image processing have allowed this once esoteric research modality to migrate into the diagnosis and staging of cancer, stroke, cardiovascular disease, and cognitive disorders like Alzheimer's, schizophrenia, autism and attention deficit disorder. Procedure volume is estimated at 30 million MRI scans in the US annually, and the number of scans is growing by 15-20% a year.

In terms of medical applications MRI could serve, the modality is still underused, and that means a large, untapped growth opportunity for the entrenched large manufacturers that dominate the industry...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Commission’s Flora Giorgio Says Simplification And Safety Are Key In Evolving EU Regs

 

Predictability, proportionality, stability, harmonization and simplification offer the right way forward to address the challenging unintended effects of the EU medical device regulations, the European Commission’s head of devices tells the EU’s largest annual medtech conference.

German Bionic Launches ‘Strongest Exoskeleton To Date’

 

German Bionic’s new exoskeleton Exia helps healthcare practitioners, nurses, and other caregivers to lift and move patients by supporting muscle movement and reducing the risk of injury.

Medtronic Eyes Up to $350M Tariff Hit in FY26, Leans On Cost Controls And Pricing Strategy

 
• By 

Medtronic expects operating profit to grow approximately 7% in fiscal 2026, excluding tariff impacts. If tariffs materialize at the upper end of the projected range, operating profit growth could drop by 2.2 to 3.2 percentage points.